ProCE Banner Activity

Dosing and Safety of PARP Inhibitors in Ovarian Cancer: Tips From My Clinic

Clinical Thought
Read this expert commentary to gain practical clinical insights on managing adverse events associated with PARP inhibitors to maximize clinical benefit for patients with ovarian cancer.

Released: August 27, 2019

Expiration: August 25, 2020

No longer available for credit.

Share

Faculty

Laura Alwan

Laura Alwan, PharmD, BCOP

Clinical Instructor
University of Washington School of Pharmacy
Oncology Clinical Pharmacist
Seattle, Washington

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by independent educational grants from

Clovis Oncology

Tesaro

Faculty Disclosure

Primary Author

Laura Alwan, PharmD, BCOP

Clinical Instructor
University of Washington School of Pharmacy
Oncology Clinical Pharmacist
Seattle, Washington

Laura Alwan, PharmD, BCOP, has no relevant conflicts of interest to report.